Romosozumab Biosimilar - Research Grade

Human

SOST

>1mg/ml

Human IgG2-Kappa

Blosozumab Biosimilar - Research Grade (ICH5141), Resugosbart Biosimilar - Research Grade (ICH5817), Setrusumab Biosimilar - Research Grade (ICH5857)

https://www.imgt.org/mAb-DB/

ICH3002

Q9BQB4

Blue ice

This is a research-grade, unconjugated recombinant analog of romosozumab, an anti-sclerostin (SOST) human IgG2-kappa antibody. It is a non-therapeutic biosimilar reagent supplied strictly for research use only (RUO); it is not the clinical drug and is not intended for human or veterinary use. Built around the sclerostin target, it is useful as a well-defined tool for in-vitro and preclinical bench work: as a target-binding and neutralization reagent to probe sclerostin function in Wnt-signaling assays, as a positive or benchmarking control in antibody screening and assay development, as a reference for ADCC/effector or antibody-engineering pipelines, and as a characterized capture/detection or standardization reagent in binding studies. It is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support screening campaigns, in-vitro standards, and preclinical model work. Because it is an analog rather than the originator product, users should validate performance for their specific application and system before relying on it. SOST encodes sclerostin, a secreted glycoprotein of the DAN/cerberus family produced largely by osteocytes and expressed in bone and, at lower levels, in other tissues. Sclerostin is a key negative regulator of bone formation: it binds the LRP5 and LRP6 co-receptors and antagonizes canonical Wnt/beta-catenin signaling in osteoblasts, thereby reducing osteoblast differentiation, activity, and survival and limiting new bone deposition. It also interacts with the BMP pathway. Sclerostin expression is regulated by mechanical loading and by hormonal and cytokine signals, allowing bone mass to adapt to skeletal demand. Loss-of-function mutations in SOST cause the high-bone-mass disorders sclerosteosis and van Buchem disease, underscoring its role as a brake on bone accrual. Neutralizing sclerostin releases this brake, increasing Wnt-driven bone formation, which is the biological rationale for anti-sclerostin antibodies in osteoporosis research.

Sclerostin

Detects human SOST

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Romosozumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Romosozumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Romosozumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Romosozumab that binds human SOST.